证券代码：002332 证券简称：仙琚制药 公告编号：2023-025 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2023年4月26日发布了《2022 年年度报告》、《2023年一季度报告》，为便于广大投资者深入全面地了解公司情 况，公司将举办投资者接待日活动，现将有关事项公告如下： 一、活动时间 2023年5月23日（星期二）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2023年5月22日（上午8:30-11:00，下午14:00-16:00）与公司 董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和安 排。 联系人：沈旭红 高晶 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长张宇松先生、总经理金炜华先生、财务总监王瑶华女士、董事会秘书张 王伟先生（如有特殊情况，参与人员会有调整）。 五、注意事 ...

浙江仙琚制药股份有限公司 关于参加深圳证券交易所上市大厅集体业绩说明会的公告 证券代码：002332 证券简称：仙琚制药 公告编号：2023-024 浙江仙琚制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为进一步加强公司与投资者的沟通交流，促进投资者深入了 解公司经营情况、未来发展战略等，公司将参加由浙江省国资委和深圳证券交易 所共同组织召开的"地方国企焕新颜——在浙里 看国企"上市大厅集体业绩说 明会暨浙江国有上市公司 2022 年度集体业绩说明会，同时就公司 2022 年度业绩 情况与投资者互动交流。现将有关事项公告如下： 一、本次业绩说明会的安排 1、召开时间：2023 年 5 月 17 日（周三）下午 15：00 至 17：40 2、召开地址：深圳证券交易所上市大厅 3、召开方式：图文与直播视频转播 4、公司出席人员： 财务总监王瑶华，独立董事刘斌，董事会秘书张王伟。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导 ...

证券代码：002332 证券简称：仙琚制药 浙江仙琚制药股份有限公司投资者关系活动记录表 编号：2023-008 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2022年度业绩说明会的全体投资者 | | 时间 | 2023年04月28日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 董事长 上市公司接待人员姓名 | 张宇松 | | 总经理 | 金炜华 | | | 财务总监 王瑶华 | | | 董事会秘书 张王伟 | | | 独立董事 张红英 | | 投资者关系活动主要内容 | 1. 请公司拆分一下制剂业务中妇科、麻醉、呼吸、皮肤、普 药的毛利率，以及原料药业务中国内和国外业务的毛利率，谢 谢 | | 介绍 | 答:您好！感谢您的提问。从产品毛利率来看，皮质激素 | | | 毛利率53.97%，妇科及计生用 ...

Financial Performance - The company's operating revenue for the first quarter was CNY 957,286,011.96, a decrease of 8.75% compared to CNY 1,049,027,960.34 in the same period last year[16] - Net profit attributable to shareholders of the listed company was CNY 133,111,920.61, an increase of 4.23% from CNY 127,713,332.35 year-on-year[16] - The net cash flow from operating activities reached CNY 69,164,061.26, a significant increase of 1,065.20% compared to CNY 5,935,810.00 in the previous year[16] - Total operating income for the period was 957,286,011.96 yuan, a decrease of 8.75% compared to 1,049,027,960.34 yuan in the same period last year[24] - Total operating costs decreased by 11.69% to 794,203,612.80 yuan from 898,974,340.09 yuan in the previous year[24] - Sales expenses decreased by 30.09%, a reduction of 95.19 million yuan, mainly due to a decrease in marketing expenses[33] - Financial expenses decreased by 123.96%, a reduction of 7.29 million yuan, mainly due to decreased interest expenses and increased interest income[33] - Other income increased by 375.81% year-on-year, an increase of CNY 0.8857 million, mainly due to an increase in other operating income[39] - Other expenses decreased by 83.9% year-on-year, a decrease of CNY 4.6737 million, mainly due to the suspension of operations at Haisheng Company in the previous year[39] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,917,547,289.10, reflecting a growth of 2.66% from CNY 6,738,173,286.59 at the end of the previous year[16] - Total liabilities amounted to CNY 1.2664 billion, an increase from CNY 1.2307 billion at the beginning of the year[43] - Total equity remained stable at CNY 2.6512 billion, unchanged from the previous period[43] - Equity attributable to shareholders of the listed company was CNY 5,604,999,529.18, up 2.70% from CNY 5,457,448,911.92 year-on-year[16] - Other receivables increased by 42.24% compared to the beginning of the year, an increase of 29.92 million yuan, mainly due to the increase in other temporary payments[18] - Accounts receivable increased by 42.6% compared to the beginning of the year, an increase of CNY 1.5397 million, mainly due to an increase in accepted bills received during the collection of payments[39] - Prepayments increased by 219.14% compared to the beginning of the year, an increase of CNY 48.6421 million, primarily due to an increase in prepayments according to contracts[39] Cash Flow - Cash flow from operating activities was 69,164,061.26 yuan, significantly up from 5,935,810.00 yuan in the same period last year[26] - Cash flow from investment activities showed a net outflow of 33,293,931.92 yuan, compared to a net outflow of 63,740,310.49 yuan in the previous year[26] - Cash flow from financing activities was not detailed in the report[26] - Cash paid for debt repayment decreased by 82.2%, down CNY 53,713,400.00, attributed to reduced cash outflows for debt repayment[4] - Cash paid for dividends, profits, or interest decreased by 72.8%, down CNY 2,337,200.00, mainly due to reduced interest payments[4] - Cash received from borrowings decreased by 100% year-on-year, a decrease of CNY 110.8 million, mainly due to a reduction in borrowings in the current period[53] Shareholder Information - Zhejiang Xianju Pharmaceutical Co., Ltd. reported a total of 213,221,808 shares held by the largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd.[54] - The second largest shareholder, Li Qinjian, holds 23,307,900 shares, representing a significant stake in the company[54] - The company has a diverse shareholder base, with notable investments from various funds, including 19,649,937 shares held by China Construction Bank's fund[54] - The financial report indicates a strong interest from institutional investors, with several funds holding over 11 million shares each[54] Future Outlook - The first quarter report for 2023 is expected to provide insights into the company's performance and future outlook[57] - The company is focusing on expanding its market presence and enhancing its product offerings in the pharmaceutical sector[58] - Future guidance will likely include projections for revenue growth and strategic initiatives in research and development[58] - The company is actively pursuing new technologies and product innovations to strengthen its competitive position[58] - Market expansion strategies are being discussed to capture a larger share of the pharmaceutical market[58] - The company is considering potential mergers and acquisitions to enhance its growth trajectory and market reach[58] Other Financial Metrics - Investment income decreased by 133.6% year-on-year, down CNY 4,708,900.00, primarily due to reduced profits from associated companies[4] - Credit impairment losses increased by 47.36%, up CNY 2,829,200.00, mainly due to increased provisions for bad debts[4] - The basic and diluted earnings per share remained at CNY 0.13, unchanged from the previous year[16] - R&D expenses for the period were 41,335,925.30 yuan, down from 57,373,399.37 yuan in the previous year[24] - Other comprehensive income increased by 251.39%, an increase of 14.44 million yuan, mainly due to foreign currency translation differences[18] - Non-current asset disposal loss was CNY -1.5384 million[52] - Government subsidies recognized in the current period amounted to CNY 1.8443 million[52]

Financial Performance - The company achieved operating revenue of CNY 4,379.83 million, a year-on-year increase of 0.52%[13] - Operating profit reached CNY 878.60 million, reflecting a growth of 15.81% compared to the previous year[13] - Net profit attributable to shareholders was CNY 749.40 million, up 21% year-on-year, with earnings per share of CNY 0.76[13] - Total revenue for the year was approximately CNY 9.87 billion, with a net profit of CNY 1.78 billion, representing a year-on-year increase of 17.76%[33] - Operating cash inflow decreased by 5.01% to CNY 3.93 billion, while operating cash outflow decreased by 4.56% to CNY 3.32 billion, resulting in a net cash flow from operating activities of CNY 609 million, down 7.39%[45] - The company reported a loss of 1,818,798.95 CNY from its investment in Zhejiang Tianxian Biopharmaceutical Co. during the reporting period[56] Research and Development - The company’s R&D efforts led to the successful evaluation of multiple products, including the approval of Mifepristone tablets in March 2023[15] - The company achieved significant progress in product development, with 3 clinical trials approved and 6 ongoing, alongside 2 generic drug applications accepted and 7 projects under review[35] - The company has been enhancing its R&D capabilities, with 46 projects underway and significant advancements in formulation development, including complex formulations[35] - R&D investment amounted to ¥266,768,087.11 in 2022, reflecting a 9.61% increase from ¥243,374,020.91 in 2021[74] - R&D expenditure accounted for 6.09% of total revenue, up from 5.59% in the previous year, indicating a 0.50% increase[77] - The company is focusing on the development of new products in three major therapeutic areas, particularly in gynecology and respiratory formulations, to enrich its product line[104] - The company has multiple ongoing R&D projects aimed at obtaining drug approvals, including 12 projects in gynecology and reproductive health, which are expected to expand the product line significantly[1] Market Expansion and Strategy - The company established business connections with over 40 clients and traders across Europe, Japan, Southeast Asia, South America, the Middle East, and North Africa[9] - The company is advancing its internationalization strategy, with projects entering the FDA application phase and ongoing GMP system optimization[36] - The company aims to become one of the top ten steroid drug suppliers globally, focusing on high-value innovation and structural optimization in the pharmaceutical industry[63] - The company is actively pursuing market expansion and innovation in response to national policies encouraging research and development in the pharmaceutical sector[60] - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence[151] - The company plans to strengthen product development and enhance collaboration with distributors to expand market coverage[90] Financial Management and Investments - The investment cash inflow increased by 12.63% to CNY 868 million, while investment cash outflow decreased significantly by 47.67% to CNY 511 million, leading to a net cash flow from investing activities of CNY 358 million, a turnaround from a negative cash flow in the previous year[45] - The company has not utilized 46,896.33 million CNY of raised funds, which are currently held in a dedicated account[64] - The company raised a total of 987.36 million RMB through a private placement, with a net amount of 987.36 million RMB after deducting underwriting fees[94] - As of the reporting period, the cumulative amount of raised funds used is 548.60 million RMB, with a remaining balance of 468.96 million RMB in the special account for raised funds[94] - The company invested a total of 22,500,000 CNY during the reporting period, representing a 14.75% increase compared to the previous year's investment of 19,607,300 CNY[56] Governance and Compliance - The company has established a governance structure that complies with legal requirements, ensuring independence from major shareholders in personnel decisions[135] - The company emphasizes the importance of maintaining communication with stakeholders to balance interests and promote sustainable development[133] - The company has a dedicated supervisory board that ensures compliance and protects the rights of shareholders[131] - The company is focused on enhancing its corporate governance and compliance with regulatory standards[155] - The company adheres to information disclosure requirements, ensuring timely and accurate communication with investors[159] - The company has no significant differences in governance practices compared to legal and regulatory requirements[181] Operational Efficiency and Cost Management - The company aims to enhance production efficiency and reduce costs through the implementation of a "profit center" model and lean production tools[93] - The company is committed to optimizing its procurement processes to reduce costs through a two-tier procurement model and centralized purchasing strategies[109] - The company plans to strengthen cost control measures in response to rising management costs, including fixed asset depreciation and financial expenses[118] - The company is committed to enhancing environmental protection measures and has achieved compliance with current regulations, but anticipates potential increases in costs due to stricter future regulations[118] - The company is focused on achieving a cost advantage through green chemistry processes and efficient production organization[106] Talent Development and Management - The number of R&D personnel increased to 562, representing a growth of 7.25% compared to 2021[74] - The company is developing a comprehensive talent management strategy to cultivate a modern workforce and improve overall performance[110] - The leadership team includes members with dual degrees and expertise in engineering and economics, reflecting a diverse skill set[196][198] - The company emphasizes the importance of professional qualifications among its executives to drive strategic initiatives and operational efficiency[195] - The company is focusing on talent development to meet the demands of international competition and ensure sustainable growth[119] Industry Challenges and Risks - The company faces risks related to industry policy changes and drug price reductions, which could impact profitability[113] - The company acknowledges the high risks associated with drug research and development, including potential misalignment with market demand and increased competition post-launch, which could adversely affect profitability[142] - The company faces risks related to rising comprehensive management costs and talent shortages, which could impact operational efficiency[145] - The company reported a significant impact from national drug procurement policies, affecting pricing and sales strategies[151] - The company is actively developing new products and technologies to adapt to the national centralized procurement policy and enhance its competitive position[127]

证券代码：002332 证券简称：仙琚制药 公告编号：2023-022 浙江仙琚制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展 战略等情况，公司定于 2023 年 04 月 28 日（星期五）15:00-17:00 在"价值在线" （www.ir-online.cn）举办浙江仙琚制药股份有限公司 2022 年度网上业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 28 日（星期五）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长张宇松，总经理金炜华，财务总监王瑶华，董事会秘书张王伟，独立 董事张红英（如遇特殊情况，参会人员可能进行调整）。 浙江仙琚制药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证 ...